CStone Pharmaceuticals Partners with Pharmalink for Suemalimab Commercialization in MENA and South Africa
China-based CStone Pharmaceuticals (HKG: 2616) has announced a strategic commercial collaboration with Pharmalink Store –...
NMPA Approves Alpha Biopharma’s Zorifertinib for First-Line NSCLC Treatment with CNS Metastases
The National Medical Products Administration (NMPA) has granted approval to China-based Alpha Biopharma’s zorifertinib, commercially...
Pfizer’s Hympavzi Receives European Commission Approval for Hemophilia A and B
US pharmaceutical major Pfizer Inc. (NYSE: PFE) has announced that the European Commission (EC) has...
Guangdong Zhongsheng Pharmaceutical’s RAY1225 Shows Positive Results in Phase II Study
Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317), a China-based pharmaceutical company, has announced positive top-line...
Shenzhen Chipscreen Biosciences Announces Private Placement to Fund Drug R&D and Expansion
China-based biopharmaceutical company Shenzhen Chipscreen Biosciences Co., Ltd (SHA: 688321) has announced plans for a...
US FDA Grants ODD to Ractigen’s siRNA Therapy RAG-21 for ALS Treatment
China-based small activating RNA (saRNA) drug developer, Ractigen Therapeutics, has announced that it has received...
UCB’s Bimzelx Receives US FDA Approval for Moderate to Severe Hidradenitis Suppurativa
Belgium-based biopharmaceutical company UCB (FRA: UNC) has announced that the US Food and Drug Administration...
Alloy Therapeutics Partners with Takeda on iPSC-Derived CAR-T and CAR-NK Therapies
US-based Alloy Therapeutics Inc. has announced a strategic partnership with Japan-headquartered Takeda Pharmaceutical Co., Ltd...
BeiGene Reaches Patent Settlement with MSN Pharmaceuticals for Brukinsa
China-based BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235), which is in the process of...
Laekna and Eli Lilly & Co. Enter Clinical Cooperation to Advance Obesity Treatment LAE102
Sino-US biotech company Laekna, Inc. (HKG: 2105) has announced a significant clinical cooperation agreement with...
GSK’s Linerixibat Demonstrates Efficacy in Phase III GLISTEN Study for Cholestatic Pruritus
UK-based pharmaceutical giant GlaxoSmithKline (GSK; NYSE: GSK) has announced positive headline results from the Phase...
Astellas Pharma’s Izervay sNDA for Geographic Atrophy Receives FDA Complete Response Letter
Japan-based Astellas Pharma Inc. (TYO: 4568) has announced that its supplemental New Drug Application (sNDA)...
Bayer AG Secures Exclusive Rights to Cytokinetics’ Aficamten in Japan
Germany-based Bayer AG (ETR: BAYN) has announced a significant collaboration and license agreement with US-based...
MSD Announces Positive Topline Results from Phase III Subcutaneous Keytruda Trial
US-based Merck, Sharp & Dohme Inc., (MSD, NYSE: MRK) has released positive topline results from...
Servier and Dana-Farber Launch SHINEDoc Program, Enroll First PhD Student
French pharmaceutical company Servier and the US-based Dana-Farber Cancer Institute have announced the start of...
New Horizon Health Registers Three Medical Devices in Hong Kong’s Department of Health
Hangzhou-based New Horizon Health Ltd (HKG: 6606) has announced the successful registration of three of...
NMPA Launches ‘Medical Service Price Items’ Column with Comprehensive Sub-Sections
The National Medical Products Administration (NMPA) has taken a significant step towards enhancing transparency in...
Brii Biosciences’ Elebsiran Shows Promising Results in Phase II ENSURE Study for Chronic HBV
China-based Brii Biosciences Ltd (HKG: 2137) has published the latest data from its ongoing Phase...
Epigenic Therapeutics Receives Approval for EPI-003 Clinical Study in New Zealand
Shanghai-based Epigenic Therapeutics, a biotechnology company specializing in the development of novel gene modulation therapies,...
UCB and Biogen’s Dapirolizumab Pegol Shows Promise in Phase III SLE Study
Partners UCB (FRA: UNC) and Biogen Inc. (NASDAQ: BIIB) have announced positive results from a...